Suggestions
Chris Jones
Executive Chair and Director
The Chris Jones associated with the LinkedIn username christophermjones and identified as the Chair at Verinnogen is likely Dr. Christopher M. Jones, although the specific LinkedIn profile provided in the query does not directly mention Verinnogen.
Here are some key points about Dr. Christopher M. Jones that align with the potential match:
- He has a PhD from the Massachusetts Institute of Technology in Urban Planning and an M.S. in Nuclear Engineering/Technology & Policy from the same institution.1
- He has extensive experience in energy, infrastructure, diversity, community development, and management.1
- He was the executive director and lead maker of the Arkansas Regional Innovation Hub, which suggests a strong background in innovation and leadership.1
However, without a direct link to Verinnogen in the provided sources, it is necessary to verify this information through additional resources or his LinkedIn profile directly. If the profile mentions his role at Verinnogen, it would confirm that this is the correct individual.
Highlights
Many thanks to Thomas McCormick and Dr. Mahmoud Ghannoum for their recent article in Pathogens and Immunity, Time to Think AntiFungal Resistance. With the emergence of multidrug resistance in several fungal species their call to action includes: 1) raising awareness of fungal diseases and AR; (2) increasing efforts to discover and develop new antifungals through support of funding for Research & Development (R&D); (3) enhancing surveillance and diagnosis; and (4) implementing public health intervention and changes in clinical practice designed to limit the spread of AR and, importantly, lead to successful management of these infections.
Excellent article by Dr Manica Balasegaram in the Financial Times about the threat of antibiotic resistance to cancer patients. Infections are the second leading cause of death among cancer patients but in 2020 there was only $160M raised for antibiotic research compared to $7B in oncology. Many thanks for the work by Global Antibiotic R&D Partnership (GARDP) to fill the gap and dedicated researchers such as Soumya Palliyil, Carol Munro and Andy Porter at Brigid Biologics developing novel antifungal therapeutics to support oncology patients.
